HUP0002395A2 - Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors - Google Patents
Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitorsInfo
- Publication number
- HUP0002395A2 HUP0002395A2 HU0002395A HUP0002395A HUP0002395A2 HU P0002395 A2 HUP0002395 A2 HU P0002395A2 HU 0002395 A HU0002395 A HU 0002395A HU P0002395 A HUP0002395 A HU P0002395A HU P0002395 A2 HUP0002395 A2 HU P0002395A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- aryl
- heterocyclic
- heteroaryl
- alkynyl
- Prior art date
Links
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 239000003613 bile acid Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 239000004721 Polyphenylene oxide Substances 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229920000570 polyether Polymers 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 102220465932 Beta-1,3-glucuronyltransferase LARGE2_R13A_mutation Human genes 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- -1 SR9 Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
A találmány (I) általános képletű új benzotiepinekettartalmazó készítményekre vonatkozik ahol q értéke 1, 2, 3 vagy 4; nértéke 0, 1 vagy 2; R1 és R2 jelentése egymástól függetlenülhidrogénatom, adott esetben helyettesített alkil-, alkenil-, alkinil-,halogén-alkil-, alkil-aril-, aril-alkil-, alkoxi-, alkoxi-alkil-,dialkil-amino-, alkil-tio-, (polialkil)-aril- és cikloalkilcsoport,vagy R1 és R2 együtt a szénatommal, amelyhez kapcsolódnak, 3-10szénatomos cikloalkilidéncsoportot alkot; R3 és R4 jelentése egymástólfüggetlenül hidrogénatom, alkil-, alkenil-, alkinil-, acil-oxi-,aril-, heterociklusos, heteroaril-, OR9, NR9R10, SR9, S(O)R9, SO2R9 ésSO3R9 általános képletű csoport, ahol R9 és R10 jelentése a fenti;vagy R3 és R4 együtt =O, =NOR11, =S, =NNR11R12, =NR9 vagy =CR11R12képletű vagy általános képletű csoportot alkot, R5 és R6 jelentéseegymástól függetlenül hidrogénatom, adott esetben helyettesítettalkil-, alkenil-, alkinil-, aril-, cikloalkil-, heterociklusos,heteroaril-, kvaterner heterociklusos, kvaterner heteroaril-, SR9,S(O)R9, SO2R9 vagy SO3R9 általános képletű csoport, R7 és R8 jelentéseegymástól függetlenül hidrogénatom vagy alkil-csoport; és egy vagytöbb Rx jelentése egymástól függetlenül hidrogénatom, halogénatom,alkil-, alkenil-, alkinil-, polialkil-, acil-oxi-, aril-, aril-alkil-,halogén-alkil-, cikloalkil-, heterociklusos, heteroaril-, poliéter,kvaterner heterociklusos, kvaterner heteroaril-, OR13, NR13R14, SR13,S(O)R13, SO2R13, SO3R13, S+R13R14A, NR13OR14, NR13NR14R15, NO2,CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14,NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, NR13R18, NR18OR14,N+R9R11R12A, P+R9R11R12A, aminosav-, peptid-, polipeptid-ésszénhidrátcsoport, ahol RX egy vagy több szénatomját adott esetben O,NR13, N+R13R14A, S, SO, SO2, S+R13A, PR13, P(O)R13, P+R13R14A,fenilén-, aminosav-, peptid-, polipeptid-, szénhidrát-, poliéter- vagypolialkilcsoport helyettesít. A fenti vegyületeket és AMG CO-Areduktáz inhibitort tartalmazó gyógyszerkészítmények a hiperlipidémiaés hiperkoleszterinémia ellen hatásosak. ÓThe invention relates to preparations containing new benzothiepines of general formula (I) where q is 1, 2, 3 or 4; its value is 0, 1 or 2; R1 and R2 independently represent a hydrogen atom, optionally substituted alkyl-, alkenyl-, alkynyl-, haloalkyl-, alkyl-aryl-, aryl-alkyl-, alkoxy-, alkoxy-alkyl-, dialkylamino-, alkylthio -, (polyalkyl)aryl and cycloalkyl groups, or R1 and R2 together with the carbon atom to which they are attached form a 3-10 carbon cycloalkylidene group; R3 and R4 are independently hydrogen, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocyclic, heteroaryl, OR9, NR9R10, SR9, S(O)R9, SO2R9 and SO3R9, where R9 and R10 means the above; or R3 and R4 together form a group of the formula =O, =NOR11, =S, =NNR11R12, =NR9 or =CR11R12 or the general formula, R5 and R6 independently represent a hydrogen atom, optionally substituted alkyl-, alkenyl-, alkynyl- , aryl, cycloalkyl, heterocyclic, heteroaryl, quaternary heterocyclic, quaternary heteroaryl, SR9, S(O)R9, SO2R9 or SO3R9, R7 and R8 are independently hydrogen or alkyl; and one or more Rx are independently hydrogen, halogen, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, haloalkyl, cycloalkyl, heterocyclic, heteroaryl, polyether ,quaternary heterocyclic, quaternary heteroaryl-, OR13, NR13R14, SR13,S(O)R13, SO2R13, SO3R13, S+R13R14A, NR13OR14, NR13NR14R15, NO2,CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14,NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, NR13R18, NR18OR14,N+R9R11R12A, P+R9R11R12A, amino acid, peptide, polypeptide and carbohydrate group, where RX has one or more carbon atoms optionally O,NR13, N+R13R14A, S, SO, SO2, S+R13A, PR13, P(O)R13, P+R13R14A, phenylene, amino acid, peptide, polypeptide, substituted by a carbohydrate, polyether or polyalkyl group. Medicines containing the above compounds and AMG CO-Areductase inhibitor are effective against hyperlipidemia and hypercholesterolemia. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4066097P | 1997-03-11 | 1997-03-11 | |
| PCT/US1998/003792 WO1998040375A2 (en) | 1997-03-11 | 1998-03-10 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0002395A2 true HUP0002395A2 (en) | 2001-05-28 |
| HUP0002395A3 HUP0002395A3 (en) | 2002-12-28 |
Family
ID=21912237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0002395A HUP0002395A3 (en) | 1997-03-11 | 1998-03-10 | Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0971744A2 (en) |
| JP (1) | JP2002500628A (en) |
| CN (1) | CN1255864A (en) |
| AU (1) | AU730024C (en) |
| BG (1) | BG103793A (en) |
| BR (1) | BR9808013A (en) |
| CA (1) | CA2283575A1 (en) |
| HU (1) | HUP0002395A3 (en) |
| IL (1) | IL131872A0 (en) |
| MX (1) | MXPA99008417A (en) |
| NO (1) | NO994390L (en) |
| NZ (1) | NZ337830A (en) |
| PL (1) | PL336415A1 (en) |
| RU (1) | RU2247579C2 (en) |
| SK (1) | SK125099A3 (en) |
| WO (1) | WO1998040375A2 (en) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| AU2003241629B2 (en) * | 1999-04-19 | 2005-06-16 | Astrazeneca Ab | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| SE0000772D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| WO2001068096A2 (en) * | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| SE0003766D0 (en) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2002051396A1 (en) * | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Pharmaceutical compositions containing cyclobutene derivatives |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| CN1582151A (en) | 2001-09-08 | 2005-02-16 | 阿斯特拉曾尼卡有限公司 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
| MXPA04005864A (en) | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases. |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| CA2497345C (en) * | 2002-08-28 | 2008-10-14 | Asahi Kasei Pharma Corporation | Novel quaternary ammonium compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| CN1930137B (en) | 2004-02-27 | 2011-07-20 | 旭化成制药株式会社 | Novel benzothiazepine and benzothiepine compounds |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CA2815698C (en) | 2010-11-08 | 2019-04-30 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| SI2637668T1 (en) | 2010-11-08 | 2016-11-30 | Albiero Ab | Ibat inhibitors for the treatment of liver diseases |
| CN107375932B (en) | 2011-10-28 | 2021-12-21 | 夏尔人类遗传性治疗公司 | Bile acid recirculation inhibitor for treating children cholestatic liver disease |
| EA029581B1 (en) | 2011-10-28 | 2018-04-30 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Use of bile acid recycling inhibitors for treatment of cholestatic liver disease or pruritis |
| EP2968262A1 (en) | 2013-03-15 | 2016-01-20 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
| CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| JO3301B1 (en) | 2013-04-26 | 2018-09-16 | Albireo Ab | Crystal modifications of elobixibat |
| KR20220082931A (en) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | Solid preparation, and method for preventing or reducing discoloration thereof |
| US11701369B2 (en) | 2014-09-28 | 2023-07-18 | Huahui Health Ltd. | Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN108601744B (en) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | Oral cholestyramine formulations and uses thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| JP6954927B2 (en) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | Oral cholestyramine preparation and its use |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN110996915B (en) | 2017-08-09 | 2023-10-03 | 阿尔比里奥公司 | Cholestyramine pellet, oral cholestyramine preparation and application thereof |
| CN111032019B (en) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | Cholestyramine granules, oral cholestyramine preparation and application thereof |
| TW202015699A (en) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| AU2020218908A1 (en) | 2019-02-06 | 2021-08-26 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| WO2020161216A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| MX2021009622A (en) | 2019-02-12 | 2021-11-04 | Mirum Pharmaceuticals Inc | Methods for treating cholestasis. |
| TW202134221A (en) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| AR120676A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023504644A (en) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | Benzothiadiazepine compounds and their use as bile acid modulators |
| CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120683A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID |
| CR20220315A (en) | 2019-12-04 | 2022-10-26 | Albireo Ab | BENZOTI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| JP2023537285A (en) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
| KR20230106651A (en) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | Odevixivat for the treatment of progressive familial intrahepatic cholestasis (PFIC) |
| CN112274648B (en) * | 2020-11-23 | 2022-10-14 | 郑州大学 | Preparation method of cholesterol oxidase modified hybrid metal organic framework tumor targeting nano preparation |
| EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| US20240140922A1 (en) * | 2022-08-22 | 2024-05-02 | Enanta Pharmaceuticals, Inc. | Fused heterobicyclic antiviral agents |
-
1998
- 1998-03-10 HU HU0002395A patent/HUP0002395A3/en unknown
- 1998-03-10 EP EP98910075A patent/EP0971744A2/en not_active Withdrawn
- 1998-03-10 PL PL98336415A patent/PL336415A1/en unknown
- 1998-03-10 RU RU99121514/15A patent/RU2247579C2/en not_active IP Right Cessation
- 1998-03-10 MX MXPA99008417A patent/MXPA99008417A/en unknown
- 1998-03-10 JP JP53959498A patent/JP2002500628A/en not_active Abandoned
- 1998-03-10 WO PCT/US1998/003792 patent/WO1998040375A2/en not_active Application Discontinuation
- 1998-03-10 SK SK1250-99A patent/SK125099A3/en unknown
- 1998-03-10 IL IL13187298A patent/IL131872A0/en unknown
- 1998-03-10 NZ NZ337830A patent/NZ337830A/en not_active Application Discontinuation
- 1998-03-10 CN CN98804995A patent/CN1255864A/en active Pending
- 1998-03-10 CA CA002283575A patent/CA2283575A1/en not_active Abandoned
- 1998-03-10 AU AU64408/98A patent/AU730024C/en not_active Ceased
- 1998-03-10 BR BR9808013-0A patent/BR9808013A/en not_active IP Right Cessation
-
1999
- 1999-09-10 NO NO994390A patent/NO994390L/en not_active Application Discontinuation
- 1999-10-11 BG BG103793A patent/BG103793A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL131872A0 (en) | 2001-03-19 |
| BG103793A (en) | 2000-07-31 |
| JP2002500628A (en) | 2002-01-08 |
| SK125099A3 (en) | 2001-02-12 |
| MXPA99008417A (en) | 2005-02-03 |
| BR9808013A (en) | 2001-09-25 |
| RU2247579C2 (en) | 2005-03-10 |
| NO994390L (en) | 1999-11-04 |
| HUP0002395A3 (en) | 2002-12-28 |
| CN1255864A (en) | 2000-06-07 |
| WO1998040375A2 (en) | 1998-09-17 |
| CA2283575A1 (en) | 1998-09-17 |
| AU730024C (en) | 2004-08-05 |
| EP0971744A2 (en) | 2000-01-19 |
| AU6440898A (en) | 1998-09-29 |
| WO1998040375A3 (en) | 1998-12-03 |
| AU730024B2 (en) | 2001-02-22 |
| NO994390D0 (en) | 1999-09-10 |
| NZ337830A (en) | 2001-07-27 |
| PL336415A1 (en) | 2000-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002395A2 (en) | Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors | |
| HUP9903047A2 (en) | Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | |
| IS2833B (en) | ÉÅQ┴Bens├│├╛├¡├│sep├¡n┴og┴notkun┴├╛eirra┴gegn┴fitubl├Ó├░i┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴ | |
| IL160689A0 (en) | Benzothiazepine derivatives for treatment of hyperlipidemia | |
| DE60216127D1 (en) | Benzothiepine als ileal bile acid transport inhibotoren | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| DE60233239D1 (en) | benzothiazepine derivatives | |
| IL159087A0 (en) | Bridged bicyclic compounds and pharmaceutical compositions containing the same | |
| MXPA04008806A (en) | New inhibitors of histone deacetylase. | |
| EA199900937A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING VORIKONAZOL | |
| PL370990A1 (en) | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | |
| HUP0302248A2 (en) | Cyanopyrrolidine derivatives and pharmaceutical compositions containing them | |
| IL157816A0 (en) | Steroids as agonists for fxr | |
| PL370982A1 (en) | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | |
| IL175409A0 (en) | Oxazolidinone-quinolone hybrid derivatives and pharmaceutical compositions containing the same | |
| IL160769A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| AP1541A (en) | New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors. | |
| TW200740781A (en) | Novel compounds | |
| EA200601687A1 (en) | Tetrahydroisoquinoline TETRAGIDROBENZAZEPINOVYE AND DERIVATIVES (OPTIONS), pharmaceutical compositions and pharmaceutical kits, medicinal and reference instruments for the test-systems based on them, methods of treatment and prevention of diseases in which the down-regulation of a favorable or inhibiting the expression or function of IGF-1 Receptor | |
| DE60314381D1 (en) | BENZYLIMIDAZOLYL SUBSTITUTED 2-CHINOLONE AND CHINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | |
| CY1105798T1 (en) | STEPOIDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES OF THE COMPOUNDS | |
| HUP0301553A2 (en) | Pharmaceutical compositions and their use for treating neurological disorders | |
| AU2002248531A1 (en) | Pyrazolopyriadine derivatives | |
| EP1142883A4 (en) | Novel heterocyclic compounds and drug compositions containing the same | |
| HUP0300887A2 (en) | Pharmaceutical compositions containing steroidal structures and uses thereof |